MedTrace Logo

Microbiota and Probiotic Therapy in Ulcerative Colitis Patients

NCT07180186 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2025-09-18

No results posted yet for this study

Summary

This study aimed to evaluate the role of microbiota and probiotics in Egyptian patients with ulcerative colitis.

Conditions

Interventions

DRUG

Mesalamine

Patients with ulcerative colitis in remission treated with oral mesalamine.

DRUG

Probiotics (Bacillus Clausii)

Patients with ulcerative colitis in remission treated with probiotics (Bacillus Clausii).

DRUG

Mesalamine and probiotics (Bacillus Clausii)

Patients with ulcerative colitis in remission treated with oral mesalamine and probiotics (Bacillus Clausii).

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-05-01
Completion
2024-05-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07180186 on ClinicalTrials.gov